表紙
市場調查報告書

診斷用放射性醫藥品及顯影劑的全球市場 - 成長,趨勢,預測(2019年∼2024年)

Diagnostic Radiopharmaceuticals & Contrast Media Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 391409
出版日期 內容資訊 英文 118 Pages
商品交期: 2-3個工作天內
價格
Back to Top
診斷用放射性醫藥品及顯影劑的全球市場 - 成長,趨勢,預測(2019年∼2024年) Diagnostic Radiopharmaceuticals & Contrast Media Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年02月01日內容資訊: 英文 118 Pages
簡介

全球診斷用放射性醫藥品及顯影劑市場,技術開發,及各種疾病的診斷的用途擴大,政府支援,慢性疾病的增加等,促進成長。

本報告提供全球診斷用放射性醫藥品及顯影劑市場調查,市場概要,各放射性醫藥品、顯影劑、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 醫療圖像處理技術的進步
    • 影像支援手術及診斷的需求增加
    • 癌症及心臟疾病的盛行率上升
  • 市場阻礙因素
    • 技術成本高
    • 特定的健康保險的補償範圍
    • 放射性醫藥品的半衰期短
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場區隔

  • 各放射性醫藥品
    • 各成像模式
      • SPECT
      • PET
    • 各用途
      • 診斷
      • 治療
  • 顯影劑
    • 各用途
    • 各治療
    • 各適應症
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Bioclinica
    • Bio-Optronics Inc.
    • DATATRAK International Inc.
    • ERT Clinical
    • IBM Watson Health
    • Medidata Solutions Inc.
    • MedNet Solutions Inc.
    • Oracle Corporation
    • Parexel International Corporation
    • ArisGlobal

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 53338

Market Overview

The global diagnostic radiopharmaceuticals and contrast media market is growing at a steady rate, due to factors, such as technological developments, increasing diagnostic applications in various diseases, government support, and rising cases of chronic diseases. Also, factors, such as shorter half-life of radiopharmaceuticals, stringent regulatory framework, and high capital investment, are expected to hinder the market growth.

The development in the minimally invasive therapeutic procedures has encouraged the usage of imaging equipment. This increase in the demand for image guidance has propelled the market. Additionally, medical imaging has witnessed numerous advancements in recent times. The emerging technologies help in enhancing the resolution and quality of the medical images, in turn, propelling the demand for contrast media and diagnostic radiopharmaceuticals. Rising cancer cost is another factor, which is impacting healthcare costs. The government is taking several initiatives for better cancer management. These initiatives are likely to affect the imaging industry, as they give the multinational companies a potential place to make significant investments.

Scope of the Report

Radiopharmaceuticals are a group of pharmaceutical drugs that have radioactivity and can be used as diagnostics and therapeutic agents. Contrast media is the substance used to enhance the contrast of an image, hence, making an image more detailed and apparent. Contrast media is increasingly being used in various medical imaging techniques, such as MRI and CT. This report analyzes and discusses the global radiopharmaceuticals and contrast media market.

Key Market Trends

Cardiology Sub-segment Captured the Largest Market Share and is Expected to Retain its Dominance

The major factor driving the growth of the market is the rising prevalence of cardiovascular diseases over the world. According to the estimates of the World Health Organization (WHO), in 2016, 17.9 million people died from CVDs. SPECT, which stands for single photon emission computed tomography, is a non-invasive procedure that can accurately identify areas of abnormal myocardial perfusion. It is also used to determine the functional capacity of the heart muscle and is able to separate living tissue from an irreversibly damaged tissue. This diagnostic procedure helps physicians find out if there are blockages in the coronary (heart) arteries, as well as to determine if the patient should undergo a coronary angiogram. In SPECT, cardiac-specific radiopharmaceuticals, such as 99mTc-tetrofosmin (Myoview, GE healthcare), 99mTc-sestamibi (Cardiolite, Bristol-Myers Squibb), or Thallium-201 chloride are administered. Hence, factors, such as the rising prevalence of cardiovascular diseases and technological advancements in the field of diagnostics, are expected to drive the growth of the market over the forecast period.

North America Captured the Largest Market Share and is Expected to Retain its Dominance

North America dominated the overall diagnostic radiopharmaceuticals and contrast media market, with the United States accounting for the major contributor to the market. The US diagnostic radiopharmaceuticals and contrast media market is anticipated to continue its expansion over the forecast period. The first gadolinium-based contrast agent was approved in the United States. Four agents were approved in the United States in the past decade, and they have set a string trend in the industry to continue to find more efficient, accurate, and safe agents.

The contrast media sales are expected to increase in the United States in the coming years. Among the different imaging modalities, sales of contrast media for the ultrasound market are likely to have a considerable growth rate. Diagnostic radioisotopes are a significant component of the US economy. Increase in chronic cardiac and neurological diseases is the primary driving factor for the market growth in the United States. Hence, the North American diagnostic radiopharmaceuticals and contrast media market is expected to retain its dominance over the forecast period.

Competitive Landscape

The presence of major market players, such as Bayer AG, GE Healthcare, Cardinal Health Inc., Nordion Inc., and Siemens Healthineers, is in turn, increasing the overall competitive rivalry of the market. The scarce presence of few companies operating in this sector, along with factors, such as powerful competitive strategy and strong market foothold, is resulting in the low score of the market, in terms of competitive rivalry.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Technology Advancements in Medical Imaging
    • 4.2.2 Increasing Demand for Image-guided Procedures and Diagnostics
    • 4.2.3 High Prevalence of Cancers and Cardiac Diseases
  • 4.3 Market Restraints
    • 4.3.1 High Costs of the Techniques- Not Easily Affordable
    • 4.3.2 Limited Health Insurance Coverage
    • 4.3.3 Short Half-life of Radiopharmaceuticals
  • 4.4 Industry Attractiveness Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Radiopharmaceuticals
    • 5.1.1 By Type of Imaging Modality
      • 5.1.1.1 SPECT
      • 5.1.1.1.1 Tc-99
      • 5.1.1.1.2 Tl-201
      • 5.1.1.1.3 Ga-67
      • 5.1.1.1.4 I-123
      • 5.1.1.1.5 Other SPECTs
      • 5.1.1.2 PET
      • 5.1.1.2.1 F-18
      • 5.1.1.2.2 Rb-82
      • 5.1.1.2.3 Other PETs
    • 5.1.2 By Application
      • 5.1.2.1 Diagnostic Application
      • 5.1.2.1.1 SPECT Applications
      • 5.1.2.1.1.1 Cardiology
      • 5.1.2.1.1.2 Neurology
      • 5.1.2.1.1.3 Thyroid
      • 5.1.2.1.1.4 Other SPECT Applications
      • 5.1.2.1.2 PET Application
      • 5.1.2.1.2.1 Oncology
      • 5.1.2.1.2.2 Cardiology
      • 5.1.2.1.2.3 Neurology
      • 5.1.2.1.2.4 Other PET Applications
      • 5.1.2.2 Therapeutic Application
      • 5.1.2.2.1 Thyroid
      • 5.1.2.2.2 Lymphoma
      • 5.1.2.2.3 Endocrine Tumors
      • 5.1.2.2.4 Other Therapeutic Applications
  • 5.2 Contrast Media
    • 5.2.1 By Application
      • 5.2.1.1 Ionizing Radiation-based Radioimaging
      • 5.2.1.2 Non-Ionizing Radiation-based Radioimaging
    • 5.2.2 By Procedure
      • 5.2.2.1 X-ray/Computed Tomography (CT)
      • 5.2.2.1.1 Iodinated Contrast Media Ionic
      • 5.2.2.1.2 Iodinated Contrast Media Non-Ionic
      • 5.2.2.1.3 Barium-based Contrast Media
      • 5.2.2.2 Magnetic Resonance Imaging (MRI)
      • 5.2.2.2.1 Gadolinium-based Contrast Media
      • 5.2.2.2.2 Other Magnetic Resonance Imaging
      • 5.2.2.3 Ultrasound
    • 5.2.3 By Indication
      • 5.2.3.1 Cardiovascular Disease
      • 5.2.3.2 Oncology
      • 5.2.3.3 Gastrointestinal
      • 5.2.3.4 Disorders
      • 5.2.3.5 Neurological
      • 5.2.3.6 Disorders
      • 5.2.3.7 Other Indications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 United Kingdom
      • 5.3.2.2 Germany
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bioclinica
    • 6.1.2 Bio-Optronics Inc.
    • 6.1.3 DATATRAK International Inc.
    • 6.1.4 ERT Clinical
    • 6.1.5 IBM Watson Health
    • 6.1.6 Medidata Solutions Inc.
    • 6.1.7 MedNet Solutions Inc.
    • 6.1.8 Oracle Corporation
    • 6.1.9 Parexel International Corporation
    • 6.1.10 ArisGlobal

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top